Antimicrobial Stewardship and Resistance
- Le cannabis au Canada – Renseignez-vous sur les faits
- Lignes directrices de réduction des risques liés à l’utilisation du cannabis au Canada
Canadian Antimicrobial Resistance Surveillance System (CARSS)
The Canadian Antimicrobial Resistance Surveillance System (CARSS) Report – 2020 is now available on the Government of Canada website.
The CARSS report provides an integrated picture of antimicrobial resistance (AMR) and antimicrobial use (AMU) in Canada, prioritizing data acquired by the Public Health Agency of Canada (PHAC) and its partners. Web links to this year’s report will be circulated shortly.
This year’s report provides details on AMR in organisms of highest concern to Canadians, as well as information on AMU in human and animal populations. In summary:
- There are indications that the AMR landscape is worsening in humans.
- AMU continues to increase in humans, particularly in elderly Canadians.
- Despite overall declines, the quantities of antimicrobials sold for use in animals increased between 2017 and 2018.
The growing trend of AMR is a problem that no entity can solve on its own. We look forward to the continued and improved integration of AMR and AMU data from all PHAC partners, as we collaboratively work towards limiting the rise of AMR infections in Canada.
Chief Public Health Officer (CPHO)
Chief Public Health Officer of Canada spotlight report on Handle with Care: Preserving Antibiotics Now and Into the Future.
This report highlights the social and cultural drivers of the unnecessary prescribing and improper use of antibiotics in Canada and describes what Canadians, health care providers, and health system leaders can do to reduce inappropriate antibiotic use and conserve their effectiveness.
- AMMI Canada: Guidance on Use of Antiviral Agents for the 2019-2020 Influenza Season
- AMMI Canada: Use of antiviral drugs for seasonal influenza: Foundation document for practitioners—Update 2019
- NACI Recommendations on fractional influenza vaccine dosing
- NCCID Webinar:Seasonal Influenza 2020-2021 Recommendations in the Context of COVID-19 Webinar
- FLU(influenza): FluWatch surveillance
- AMMI Canada Position Statement on the Diagnosis and Treatment of People with Persistent Symptoms That Have Been Attributed to Lyme Disease
- Énoncé de position de l’AMMI Canada sur le diagnostic de la maladie de Lyme et le traitement des personnes ayant des symptômes persistants attribués à cette maladie
- The Facts about Lyme disease: What You Need To Know
- Les faits sur la maladie de Lyme : Ce qu’il faut savoir
- NEW Clinical Practice Guidelines by the Infectious Diseases Society of America (IDSA): 2020 Guideline on Diagnosis and Management of Babesiosis
NEW: The internet can be a valuable source of information; it can also be difficult sometimes to tell what information is backed up by good science. Here are some reliable sites that can help answer your questions:
- Lyme Disease in Canada – A Federal Framework (English French)
- AMMI Canada’s response to the Draft Federal Framework on Lyme Disease
National Advisory Committee on Immunization (NACI)
National Advisory Committee on Immunization (NACI): Statements and publications
NACI makes recommendations for the use of vaccines currently or newly approved for use in humans in Canada, including the identification of groups at risk for vaccine-preventable diseases for whom vaccination should be targeted. NACI knowledge syntheses, analyses and recommendations on vaccine use in Canada are published in literature reviews, statements and updates.
New statements are those which have been published within the past five years. Previous statements are those which are were published over five years ago and have been archived.
NACI recommendations are also published in vaccine-specific chapters of the Canadian Immunization Guide.
- Guidance on the Prioritization of Key Populations for COVID-19 Immunization
- Orientations sur la priorisation des populations principales pour l’immunisation contre la COVID-19
- NACI Recommendations on the Use of COVID-19 Vaccine
- CCNI Recommandations sur l’utilisation des vaccins contre la COIVD-19
- Recommendations on the Duration of the Post-vaccination Observation Period for Influenza Vaccination during the COVID-19 Pandemic
- Recommendation on the Use of Live Attenuated Influenza Vaccine (LAIV) in HIV-Infected Individuals
- NACI Research Priorities for COVID-19 Vaccines to Support Public Health Decisions
- Interim guidance on continuity of immunization programs during the COVID-19 pandemic
- Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2020–2021
Email updates are available through our mailing list. To subscribe to receive instant alerts when chapter updates and new NACI products are posted.
- NEW – Statement from the Public Health Agency of Canada on Omicron Variant
- NEW – Statement from the Government of Canada on Omicron Variant
- NEW – Statement from the Honourable Jean-Yves Duclos, Minister of health on Omicron Variant
Coronanvirus disease (COVID-19): Outbreak Update and the COVID-19 Virtual Assistant – ca/coronavirus
Update on COVID-19 in Canada: Epidemiology and modelling (December 11, 2020)
Coronavirus disease (COVID-19): Vaccines
- Canada to receive early access to Moderna COVID-19 vaccine
- COVID-19 mRNA vaccines
- Vaccines and treatments for COVID-19: Progress
- Canada’s COVID-19 Immunization Plan: Saving Lives and Livelihoods
- Health Canada authorizes first COVID-19 vaccine
- COVID-19 immunization: Federal, provincial and territorial statement of common principles
- International Coalition of Medicines Regulatory Authorities statement on continuation of vaccine trials
- Vaccines and treatments for COVID-19: Vaccine rollout
- Coronavirus disease (COVID-19): Awareness resources
- READ MORE